Delafloxacin

Delafloxacin
Delafloxacin
Systematic (IUPAC) name
1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid
Clinical data
Pregnancy cat.  ?
Legal status Investigational
Identifiers
CAS number 189279-58-1
ATC code None
PubChem CID 487101
ChemSpider 427049
UNII 6315412YVF YesY
KEGG D09330
Chemical data
Formula C18H12ClF3N4O4 
Mol. mass 440.76 g/mol
SMILES eMolecules & PubChem

Delafloxacin (originally RX-3341) is a fluoroquinolone antibiotic being developed by Rib-X Pharmaceuticals, Inc.

It is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as MRSA.

Phase II clinical trials have been completed,[1][2][3] including a trial with tigecycline as a comparator[4]

References

  1. ^ http://www.bio-medicine.org/biology-technology-1/Rib-X-Pharmaceuticals-Announces-Positive-Phase-2-Study-Results-for-Delafloxacin-and-a--2425-Million-Financing-10093-1/
  2. ^ http://clinicaltrials.gov/ct2/show/NCT00719810
  3. ^ http://www.medicalnewstoday.com/articles/132200.php "Rib-X Pharmaceuticals Reports Positive Top-Line Results From Phase 2 Study Of Delafloxacin" 9 Dec 2008
  4. ^ http://www.citybizlist.com/lstg/lstgDetail.aspx?id=45749 "ABS Ventures Joins $25M Series D Rib-X Pharmaceuticals Inc." 5 Feb 2009
Stub icon This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.